All News
![](https://pbs.twimg.com/profile_images/990351876804591616/xFG36pY3.jpg)
GiACTA
What happened when weekly TCZ stopped?
42% maintained clinical remission on NO treatment at end 2yr Part2
What happened when Pred stopped (this happened in part1)?
Taper 26wk: 32% no flare over yr
Taper 52wk: 51% no flare over that yr
#ACR19 @rheumnow Abst0808
Dr Irwin Lim _connectedcare ( View Tweet)
![](https://pbs.twimg.com/profile_images/990351876804591616/xFG36pY3.jpg)
GiACTA 1: blinded injections stopped wk52
Part 2: 2yrs
Time to flare after remission
Most flares in part 1 in those randomised to GC alone
Lowest cumulative GC doses over 3y in TCZ-QW (50% less)
#ACR19 @rheumnow Abst0808
Dr Irwin Lim _connectedcare ( View Tweet)
![](https://pbs.twimg.com/profile_images/990351876804591616/xFG36pY3.jpg)
GiACTA Part 1 at conclusion, different gps obvious:
In remission no treatment
In remission on treatment
Recently active, on treatment
GiACTA Part 2 Aims:
Long term safety of TCZ-treated GCA
Explore maintenance of efficacy after TCZ discontinuation
#ACR19 @rheumnow Abst0808
Dr Irwin Lim _connectedcare ( View Tweet)
![](http://pbs.twimg.com/media/EJCtoDJUcAAHZFl.jpg)
FINCH3: in this cohort naive to MTX pre-trial, interesting that safety looks good! Maybe too early to tell
#ACR19 @rheumnow Abst0927 #ACRbest https://t.co/QCdC8UQR3f
Dr Irwin Lim _connectedcare ( View Tweet)
![](http://pbs.twimg.com/media/EJCz91pUEAAovIn.jpg)
Fenebrutinib- Conclusions from phase2. How does this compare to our other small molecules? Will trial development continue?
#ACR19 @rheumnow Abst0929 https://t.co/5ahkmSB11X
Dr Irwin Lim _connectedcare ( View Tweet)
![](http://pbs.twimg.com/media/EI95fD7WoAI2PkN.jpg)
Awesome to hang out with my friends @psufka and @DrBhana to record an episode of ACR on Air on location at #ACR19 ! https://t.co/WeolRLGs17
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJBe5vQXkAIWzhB.jpg)
25% of SLE and RA patients at this academic practice were receiving HCQ above recommended doses, by @SkorupaTara & @RobShmerling #ACR19 @rheumnow #Abstr #ACRBest https://t.co/pq379l9ZPH
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJBkuyEXUAAcos6.jpg)
Holy smokes! 18x higher risk of cardiovascular disease in Black SLE patients, highest at 1 and 10 years after diagnosis - Dr Shivani Garg #ACR19 @rheumnow #Abstr #ACRBest https://t.co/kXoMNu4QKb
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJBoG9jX0AA7EO4.jpg)
A second study (after MAINRITSAN) showing the superiority of rituximab vs. azathioprine for maintenance of remission in ANCA-associated vasculitis, by Dr. Rona Smith #ACR19 @rheumnow #Abstr #ACRBest https://t.co/H8VJiFhp6z
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJBwF3mWsAEqdGv.jpg)
GCA is really a chronic disease, difficult to maintain remission off meds, regardless of initial treatment strategy. Findings from Part 2 of the GIACTA trial of tocilizumab for GCA. Dr. John Stone #ACR19 @rheumnow #Abstr #ACRBest https://t.co/gxdQrH0pUj
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJB23ZSWkAELR2K.jpg)
BeSt for Kids study showed comparable efficacy of sequential monotherapy, MTX+pred, or MTX+Etanercept. However, many patients had TNFi added or TNFi switched to achieve inactive disease #ACR19 @rheumnow #Abstr #ACRBest https://t.co/p5xdJznNhN
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJB3rvCXUAAeUUk.jpg)
Amazing! Most patients with systemic JIA who receive anakinra as first line monotherapy achieved drug-free remission. Dr Ravelli #ACR19 @rheumnow #Abstr #ACRBest https://t.co/cWUdUo6dmM
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJB4-oUWwAAKqh9.jpg)
Systemic JIA may be a biphasic disease with early autoinflammatory phenotype and later autoimmune features. Dr. Ravelli #ACR19 @rheumnow #Abstr #ACRBest https://t.co/CsZeBOqeRH
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJB5uqfXYAE1-_1.jpg)
Interesting to see worldwide differences is JIA subtypes and ages of onset. Dr Ravelli #ACR19 @rheumnow #Abstr #ACRBest https://t.co/MdrPTmixw9
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJB8AF4XsAEjja_.jpg)
New Eurofever / PRINTO criteria for #autoinflammatory diseases. Dr. Ravelli #ACR19 @rheumnow #Abstr #ACRBest https://t.co/S35Ltegz1F
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJB9gGbXkAA_hRF.jpg)
Cool view of the immune system as a spectrum from immunodeficiency to autoimmunity. Dr Binstadt #ACR19 @rheumnow #Abstr #ACRBest https://t.co/b77LA9HbHQ
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJCFz8NW4AEX9Ez.jpg)
A wall of donuts. That is the best thing I’ve seen at #ACR19 https://t.co/GS6WntpCFc
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJCIn_qXsAANrTX.jpg)
The Knowledge Bowl...One of my favorite sessions of every Annual Meeting! #ACR19 https://t.co/p8aArZFbZe
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJCVDn-WwAMvY-F.jpg)
Members of all species are enjoying #ACR19! @rheumnow #Abstr #ACRBest https://t.co/rYYsTcDEKe
Jonathan Hausmann MD hausmannMD ( View Tweet)
![](http://pbs.twimg.com/media/EJCwrEIXUAEukGE.jpg)
The MS score helps diagnose MAS in patients with systemic JIA. Dr. Francesca Minoia #ACR19 @rheumnow #Abstr #ACRBest https://t.co/TO4EORxn5v
Jonathan Hausmann MD hausmannMD ( View Tweet)